ConductScience.org, home

Paper42865026PubMed

Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.

Guo Y and 22 others. Liver Int, 2026.

Cite this record

ConductScience Library. Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study. Papers, record 42865026. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42865026

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.
Journal
Liver Int
Year
2026
Publication types
Journal Article, Clinical Trial, Phase II, Randomized Controlled Trial
Revised in PubMed
2026-10-15

Source PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guo YYuminghttps://orcid.org/0000-0003-3149-8422
2Xu ZZhe
3Li YYuanyuanhttps://orcid.org/0009-0008-5724-3464
4Mao JJohn
5Zhang TTianxiang
6Li YYonggang
7Meng FFanpinghttps://orcid.org/0000-0003-3763-8115
8Fu JJunlianghttps://orcid.org/0009-0001-8318-6888
9Ji DDonghttps://orcid.org/0000-0001-8214-462X
10Ji YYingjie
11Cheng YYongqian
12Zhang MMinhttps://orcid.org/0000-0003-2497-6748
13Zhang XXin
14Sun YYinghttps://orcid.org/0000-0002-2570-9206
15Huang ZZuxionghttps://orcid.org/0000-0003-0994-0384
16Cai DDachuanhttps://orcid.org/0000-0003-3269-8549
17Wu WWenqiang
18Yan WWenhao
19Yan XXiuping
20Li GGuoping

Source PubMed

See all 23 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis B, ChronicMajor topic
Antiviral AgentsMajor topic
Hepatitis B virusMajor topic
Humans
Double-Blind Method
Male
Adult
Female
Middle Aged
Hepatitis B Surface Antigens
Treatment Outcome
DNA, Viral
Benzoxepins
Pyridines

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Akeylink Biotechnology Co. Ltd.PubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06263959A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis BDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133099752Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.Hepatol Int2020https://conductscience.org/library/papers/33099752PubMed
236453086Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon.Liver Int2023https://conductscience.org/library/papers/36453086PubMed
335092743Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.J Hepatol2022https://conductscience.org/library/papers/35092743PubMed
441107676Combination therapies for chronic hepatitis B in the era of emerging novel drugs.Hepatol Int2026https://conductscience.org/library/papers/41107676PubMed
533889654Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients.Open Forum Infect Dis2020https://conductscience.org/library/papers/33889654PubMed
636089112Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.Bioorg Med Chem Lett2022https://conductscience.org/library/papers/36089112PubMed
721410068Application of interferon response-related gene array to the antiviral treatment outcome in chronic hepatitis C.Hepatogastroenterology2010https://conductscience.org/library/papers/21410068PubMed
836727229[Clinical effect and influencing factors of pegylated interferon alfa-2a and entecavir monotherapy among children with HBeAg-positive chronic hepatitis B based on a real-world study].Zhonghua Gan Zang Bing Za Zhi2022https://conductscience.org/library/papers/36727229PubMed
933486874Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens.Liver Int2021https://conductscience.org/library/papers/33486874PubMed
1034371538[Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance].Zhonghua Gan Zang Bing Za Zhi2021https://conductscience.org/library/papers/34371538PubMed
1134435408Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials.J Viral Hepat2021https://conductscience.org/library/papers/34435408PubMed
1234593151Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa.Clin Liver Dis2021https://conductscience.org/library/papers/34593151PubMed
1319338056Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.Hepatology2009https://conductscience.org/library/papers/19338056PubMed
1442865026Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.Liver Int2026https://conductscience.org/library/papers/42865026PubMed
1536408671A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon.Clin Pharmacol Ther2023https://conductscience.org/library/papers/36408671PubMed
1621994680Antiviral treatment of chronic hepatitis B virus (HBV) infections.Viruses2010https://conductscience.org/library/papers/21994680PubMed
1734225435[Clinical analysis of four cases of HBsAg seroconversion in patients with HBeAg-positive chronic hepatitis B after receiving interferon alpha therapy].Zhonghua Gan Zang Bing Za Zhi2021https://conductscience.org/library/papers/34225435PubMed
1835257963Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.Virol Sin2022https://conductscience.org/library/papers/35257963PubMed
1933896094Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers.Liver Int2021https://conductscience.org/library/papers/33896094PubMed
2025733157The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.J Hepatol2015https://conductscience.org/library/papers/25733157PubMed

See all 30 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first.

PMIDTitleJournalYearIn Papers
42865026Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.Liver Int2026https://conductscience.org/library/papers/42865026

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42865026

GET https://conductscience.org/api/papers/v1/42865026/authors?page=2